跳至主要内容
临床试验/ISRCTN77098312
ISRCTN77098312已完成不适用

Treatment of hyperphenylalaninemia with Sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) and its influence on the amino acids and fatty acids patterns from childhood to adulthood, a Phase IV, longitudinal, unblinded, controlled, single-centre, retrospective and prospective clinical study

Aragon Institute of Health Sciences [Instituto Aragonés de Ciencias de la Salud] (Spain)0 个研究点目标入组 30 人开始时间: 2011年4月18日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Patients with hyperphenylalaninemia due to phenylalanine hydroxylase deficiency, who respond to treatment with Sapropterin
  • 2. Childbearing women who should have a negative pregnancy test within 7 days prior to start of treatment with Sapropterin and should use reliable contraception during the whole study
  • 3. The control group will include patients with hyperphenylalaninemia due to phenylalanine hydroxylase deficiency that are metabolically well controlled without Sapropterin

排除标准

  • 1. Liver impairment or other underlying chronic disease that may require regular treatment
  • 2. Pregnancy and breastfeeding

研究者

发起方
Aragon Institute of Health Sciences [Instituto Aragonés de Ciencias de la Salud] (Spain)

相似试验